Month: August 2022

WALL, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) and large-scale identity solutions, featuring Identity-Bound Biometrics (IBB), today reported results for its second quarter ended June 30, 2022 (Q2’22). BIO-key is hosting a conference call today at 10:00 a.m. ET (details below) to review its results and outlook. Highlights:Q2’22 revenues rose 96% to $1.9M from $1.0M in Q2’21, driven by a $0.5M increase in software license fees, as well as $0.3M and $0.15M increases in hardware and services revenue, respectively. Expanded PortalGuard Penetration with new customers, including YYK Enterprises Operations and a Texas City and New Channel Alliance Program partners, including the Amazon Web Services Partner...

Reports second quarter 2022 commercial revenue of $3.9 million Lowers full year 2022 commercial revenue guidance to at least $17.0 million Implements organizational restructuring plan to right-size cost structure with focus on enhancing commercial execution and key product development programs to drive revenue growth CEO Robert Spignesi to assume commercial leadership responsibilities Announces review of strategic alternatives and rejection of Kennedy Lewis Management Proposal LOWELL, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended...

Company announcement no. 9 – 22 12 August 2022 NTG Nordic Transport Group publishes interim report for H1 2022 and launches share buy-back program NTG publishes interim report for H1 2022 The interim report for H1 2022 is enclosed. In connection with publication of the results for H1 2022, a conference call will be hosted on 15 August 2022 at 10:00 AM CEST. The conference call will be held in English and can be followed live via NTG’s website; investor.ntg.com. NTG launches share buy-back program The Board of Directors of NTG has decided to launch a share buy-back program in accordance with the authorisation granted to the Board of Directors on the Annual General Meeting held 16 April 2020. The authorisation covers share buy-backs up to a maximum of 10% of the Company’s share capital at any given time and is valid until 16 April...

– Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful improvement in BCVA and CST with favorable safety profile at 12 and 18 weeks – – Near-Term Milestones include 24-week Data in BEHOLD and 16-week Data in Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration by Year-End – – Tie2/VEGF Bispecific Program Achieved Advanced Candidate Nomination – – As of June 30, 2022, UNITY had approximately $64.5 million in cash, cash equivalents and marketable securities, providing runway through Q1 2023 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology...

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2022. Second Quarter 2022 Summary & Operating Highlights:Total revenue of $27.3 million, up $1.4 million, or 6%, year-over-year.U.S. revenue up 7% year-over-year. Total subscription and system revenue up 9% year-over-year.GAAP net loss attributable to stockholders of $10.6 million, compared to net income of $0.4 million last year.Second quarter 2021 GAAP net loss attributable to stockholders included approximately $6 million of non-cash gain and bad debt recovery which did not benefit GAAP net loss attributable to stockholders in the second quarter of 2022.Adjusted EBITDA loss of $5.5...